Cencora Announces Financial Leadership Transition
Mr. Cleary, 62, has served as Cencora’s CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a decade.
“On behalf of the Board and Enterprise Leadership Team, I want to thank Jim for his years of pragmatic leadership, strategic insight and consistent financial stewardship,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “Jim retires with an outstanding track record of driving growth and shareholder value during his over 20 years as a public company executive.”
“I have had the pleasure of working with Jim for twelve years,” said Mark Durcan, Chair of Cencora’s Board of Directors. “He is a consistent, thoughtful and practical leader with a demonstrated track record of connecting strategic vision and business acumen for the organizations he’s been a part of. We appreciate that Jim will remain with Cencora for the next several months and we wish him the best in his next chapter.”
“Working with this team has been the highlight of my career,” said Cleary. “I’m very proud of what we accomplished together at Cencora, enhancing value for all stakeholders. As I step into my next chapter, I do so with great confidence in Cencora and the talented people across the company.”
Cencora is also reaffirming its previously issued adjusted diluted EPS guidance range of $17.45 to $17.75 for fiscal year 2026.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $300 billion in annual revenue. Learn more at investor.cencora.com